Design Therapeutics, Inc.
NASDAQ:DSGNBiotechnology
+$0.19 today
- Market cap
- $606.42M
- Beta
- 1.66
- P/E (TTM)
- -10.7
- EPS (TTM)
- -$1.13
Volume 0.32M
Average 0.74M
DSGN Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Design Therapeutics, Inc.NASDAQ: DSGN
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation grows in line with its trailing trend
Q1 FY2026 stock-based compensation of $3.92M rose 10.9% year over year, in line with the +11.2% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 14.2% from the prior quarter. Over 3 fiscal years it compounded at +10.0% a year.
Context
- Stock-based compensation increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +10.9% toward the trailing-twelve-month pace of +11.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 14.55M USD
- Year-over-year change
- +11.3%
- 4-year CAGR
- +32.7%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 14.55M | +11.3% |
| FY2024 | 2024-12-31 | 13.07M | -0.1% |
| FY2023 | 2023-12-31 | 13.09M | +19.8% |
| FY2022 | 2022-12-31 | 10.93M | +133.0% |
| FY2021 | 2021-12-31 | 4.69M | — |
Stock-Based Compensation vs competitors
How DSGN compares with its peers on the latest reported figures
- DSGN's LTM Mar 2026 stock-based compensation of $14.93M is the 8th largest of the 11 companies compared; the peer median is $23.97M.
- Its year-over-year change of +11.2% is the 4th highest of 11, against a peer median of -6.4%.
- Over three fiscal years its annual growth of +10.0% compares with a peer median of +10.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $132.29M | +4.4% | +10.1% | 13.8% | |
| LTM Mar 2026 | $111.37M | -39.8% | -19.1% | 5.1% | |
| LTM Jun 2026 | $84.66M | +15.0% | -12.3% | 8.4% | |
| LTM Jun 2026 | $39.28M | -8.1% | +44.6% | — | |
| LTM Mar 2026 | $26.2M | -9.4% | +12.2% | 81.7% | |
| LTM Mar 2026 | $21.73M | +42.8% | — | 30.3% | |
| LTM Mar 2026 | $18.73M | +52.9% | +30.9% | — | |
| LTM Mar 2026 | $14.93M | +11.2% | +10.0% | — | |
| LTM Mar 2026 | $13.16M | -4.7% | -2.3% | — | |
| LTM Mar 2026 | $10.03M | -22.0% | +30.6% | — | |
| LTM Mar 2026 | $7.15M | -15.9% | +1.9% | — | |
| Peer median (excluding DSGN) | $23.97M | -6.4% | +10.1% | 13.8% | |
Competitors are the stored peer set for DSGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (35.53M) | (63.31M) | (66.86M) | (49.59M) | (69.79M) |
| Depreciation & Amortization | 129K | 406K | 537K | 596K | (2.63M) |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.69M | 10.93M | 13.09M | 13.07M | 14.55M |
| Change in Working Capital | 1.4M | 1.99M | 728K | (993K) | 3.11M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.41M | 5.39M | (1.25M) | (1.22M) | 4.49M |
| Other Working Capital | (1.02M) | (3.39M) | 1.97M | 226K | (1.38M) |
| Other Non-Cash Items | (58K) | (1.33M) | (6.05M) | (6.19M) | 406K |
| Operating Cash Flow | (29.38M) | (51.32M) | (58.56M) | (43.11M) | (54.36M) |
| Capital Expenditures | (1.54M) | (918K) | (256K) | (340K) | (193K) |
| Acquisitions (Net) | 52.11K | 39K | 0 | 0 | 0 |
| Purchases of Investments | (86.26M) | (313M) | (224.7M) | (230.18M) | (291.78M) |
| Sales of Investments | 34.16M | 92.89M | 277.5M | 274.47M | 314.89M |
| Other Investing Activities | (52.11K) | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (53.64M) | (220.99M) | 52.54M | 43.96M | 22.91M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 254.27M | 662K | 724K | 513K | 25.74M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 228K | (427K) | 0 | 0 | 0 |
| Financing Cash Flow | 379.21M | 235K | 724K | 513K | 25.74M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 296.19M | (272.07M) | (5.3M) | 1.36M | (5.71M) |
| Free Cash Flow | (30.92M) | (52.24M) | (58.82M) | (43.45M) | (54.55M) |
Design Therapeutics, Inc.
NASDAQ:DSGN
Intrinsic Alpha fair value
Locked
Current Price
$9.47
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.